Comparative Pharmacology
Head-to-head clinical analysis: ENULOSE versus LAXILOSE.
Head-to-head clinical analysis: ENULOSE versus LAXILOSE.
ENULOSE vs LAXILOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lactulose is a synthetic disaccharide that is not absorbed from the gastrointestinal tract. It is metabolized by colonic bacteria to form low molecular weight organic acids, which lower the colonic pH and increase osmotic pressure, resulting in increased stool volume and laxative effect. In hepatic encephalopathy, the acidification of the colon inhibits the growth of ammonia-producing bacteria and promotes the conversion of ammonia to ammonium ion, which is trapped in the colon and excreted, thereby reducing systemic ammonia levels.
Laxilose (lactulose) is a synthetic disaccharide that is not absorbed in the small intestine. In the colon, it is metabolized by bacteria to short-chain fatty acids (e.g., lactic, acetic, formic acids), which osmotically draw water into the bowel lumen, stimulating peristalsis and softening stools. Additionally, in hepatic encephalopathy, colonic acidification traps ammonia (NH3) as ammonium (NH4+), reducing systemic ammonia absorption.
15-45 mL orally once daily, titrated to produce 2-3 soft stools per day. Maximum 60 mL per day.
10-20 g (15-30 mL) orally once daily; may increase to 40 g (60 mL) daily in divided doses.
None Documented
None Documented
Terminal elimination half-life is 2.1 hours in normal renal function; prolonged to up to 6 hours in renal impairment.
Terminal elimination half-life is 2.5-4 hours in patients with normal renal function; prolonged to up to 20 hours in severe renal impairment.
Primarily renal (95% unchanged by glomerular filtration); biliary/fecal less than 5%.
Primarily renal excretion, with approximately 40% of the dose recovered as unchanged drug in urine; biliary/fecal excretion accounts for the remainder, including metabolites.
Category C
Category C
Laxative
Laxative